ArticleFrontiers in oncology2012
AZT as a telomerase inhibitor.
Article in Frontiers in oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 58 citations in OpenAlex.
- Quinobenzothiazine-AZT Hybrids Linked via 1,2,3-Triazole: Rational Design, Synthesis, and Biological Evaluation as Anticancer Agents.International journal of molecular sciences · 2026Article
- Hybrid and Chimeric Heterocycles for the Inhibition of Carbonic Anhydrases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Telomere-related DNA damage response pathways in cancer therapy: prospective targets.Frontiers in pharmacology · 2024Review
- T cell senescence: a new perspective on immunotherapy in lung cancer.Frontiers in immunology · 2024Review
- Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.Nature reviews. Cancer · 2022Review
- Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs.Nature communications · 2020Article
- Azidothymidine "Clicked" into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors.Journal of medicinal chemistry · 2020Article
- New drugs are not enough‑drug repositioning in oncology: An update.International journal of oncology · 2020Review
- Review
- Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV.Journal of immunology research · 2020Review
- Molecular and structural basis of nucleoside diphosphate kinase-mediated regulation of spore and sclerotia development in the fungusThe Journal of biological chemistry · 2019Article
- A non-natural nucleotide uses a specific pocket to selectively inhibit telomerase activity.PLoS biology · 2019Article
- Revitalizing the AZT Through of the Selenium: An Approach in Human Triple Negative Breast Cancer Cell Line.Frontiers in oncology · 2018Article
- Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.Infectious agents and cancer · 2018Review
- Rho GTPases as therapeutic targets in cancer (Review).International journal of oncology · 2017Review
- Article
- The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.Acta neuropathologica communications · 2017Article
- Azidothymidine inhibits cell growth and telomerase activity and induces DNA damage in human esophageal cancer.Molecular medicine reports · 2017Article
- Deficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1.Cell cycle (Georgetown, Tex.) · 2017Article
- New prospects for targeting telomerase beyond the telomere.Nature reviews. Cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomerase is a highly specialized reverse transcriptase (RT) and the maintenance of telomeric length is determined by this specific enzyme. The human holoenzyme telomerase is a ribonucleoprotein composed by a catalytic subunit, hTERT, an RNA component, hTR, and a group of associated proteins. Telomerase is normally expressed in embryonic cells and is repressed during adulthood. The enzyme is reexpressed in around 85% of solid tumors. This observation makes it a potential target for developing drugs that could be developed for therapeutic purposes. The identification of the hTERT as a functional catalytic RT prompted studies of inhibiting telomerase with the HIV RT inhibitor azidothymidine (AZT). Previously, we have demonstrated that AZT binds preferentially to telomeres, inhibits telomerase and enhances tumor cell senescence, and apoptosis after AZT treatment in breast mammary adenocarcinoma cells. Since then, several studies have considered AZT for telomerase inhibition and have led to potential clinical strategies for anticancer therapy. This review covers present thinking of the inhibition of telomerase by AZT and future treatment protocols using the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.